European bismuth prices rocket to record highs on China export curbs
March 19 (Reuters) - Bismuth prices in Europe have surged to all-time highs as China's export controls squeeze supplies of the mineral used in atomic research, cosmetics and pharmaceuticals, according to traders and experts.
Prices of bismuth have jumped to $40 a lb on the European spot market, an all-time high, up from $6 per lb in late January, a more than six-fold rise.
Get a look at the day ahead in U.S. and global markets with the Morning Bid U.S. newsletter. Sign up here.
In the United States, bismuth prices are even higher - at $55 a lb compared with $6.5-$7 before China's export curbs.
Traders said U.S. prices were also higher because of the tariffs imposed by U.S. President Donald Trump on imports from top producer China.
China in February announced plans to impose export controls on five key metals, opens new tab - tungsten, tellurium, molybdenum, bismuth, and indium - in response to Trump's import tariffs.
"At the moment there are no supply sources to fully replace Chinese material," commodity analysts with business intelligence company CRU Group told Reuters.
"As much of the supply tightness is based on policy, it can ease very quickly. But assuming a full stop of Chinese bismuth exports, new capacity ex-China would be necessary."
According to the U.S. Geological Survey (USGS), China was responsible for producing around 13,000 metric tons of mined bismuth last year or more than 80% of the global total. The rest comes from countries such as Japan, South Korea, and Laos.
Prices have risen significantly, making it risky to ship materials for stockpiling since delivery takes about two months and no one knows where the market will be by then, said a Europe-based trader.
"This situation is causing a very low unsold inventory level internationally, keeping the price for prompt material at a very high level," he added.
Meanwhile, the most active bismuth contract on the Wuxi Stainless Steel Exchange was trading at 163,800 yuan ($22,677) per metric ton on Tuesday, 105% higher than at the beginning of the year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
Short-seller Chanos questions bitcoin-holding pioneer Strategy's valuation premium
June 12 (Reuters) - Prominent short-seller Jim Chanos has questioned Strategy's (MSTR.O), opens new tab valuation premium over its bitcoin holdings, saying Chairman Michael Saylor's tactics to boost the company's returns are "financial gibberish." "...Mr. Saylor wants you to value his business based not only on the net value of his Bitcoin holdings (NAV) at market, but additionally with a multiple on the change in that NAV...," he said in a post on X on Tuesday. Also, in an interview with Bloomberg Television on Wednesday, Chanos said that Strategy's market value should not exceed the value of its bitcoin holdings. As of June 9, the company held 582,000 bitcoins, worth $62.27 billion, while its market value of $108 billion was about 1.74 times its crypto holdings. Chanos and other Strategy critics have argued that this disconnect was creating an arbitrage opportunity for buying the cryptocurrency and shorting the firm's shares. Strategy did not immediately respond to a Reuters request for comment. Following Strategy's footsteps, companies like GameStop (GME.N), opens new tab and U.S. President Donald Trump's Trump Media & Technology (DJT.O), opens new tab have also pivoted their operations to building bitcoin reserves. Strategy's shares are up nearly 34% this year, eclipsing bitcoin's 14.2% climb. Saylor has argued that critics overlook his company's innovative use of bitcoin-backed financial instruments, which he insists justify the premium at which the company trades and protect it from the risks Chanos highlights. The company actively issues bitcoin-backed credit instruments, such as non-cumulative preferred stock, allowing it to raise capital without diluting common shareholders or taking on traditional debt obligations.
Reuters
an hour ago
- Reuters
One Cycling project not included in next season's UCI calendar
June 12 (Reuters) - The UCI opted not to include the One Cycling project when it launched its World Tour and Women's World Tour calendars for 2026 on Thursday, with the governing body saying it was incompatible with its regulatory framework. The project, reportedly backed by an investment firm owned by Saudi Arabia's Public Investment Fund (PIF), aims to revolutionise cycling with the support of major teams and race organisers. One Cycling wanted an overhaul of the calendar and the possible creation of new competitions to generate new sources of revenue. "The project, which had been developed by certain teams and organisers in collaboration with a sports investment fund, was deemed incompatible with the governance and regulatory framework of the UCI as well as lacking sporting coherence," a UCI press release said. The UCI said it welcomed the fact that cycling is attracting new investors and wished to continue discussions with the project's representatives. There is one addition to the women's calendar with the Dwars door Vlaanderen on April 1, after the race had previously been run on the UCI ProSeries calendar, the second-tier tour. In an effort to promote the continued development of women's cycling, the UCI Management Committee approved a 20% increase in the participation allowance paid by organisers of Women's World Tour events to participating teams.
Reuters
an hour ago
- Reuters
Kenvue mulls sale of some skin health and beauty brands, sources say
NEW YORK, June 12 (Reuters) - Kenvue (KVUE.N), opens new tab is exploring the sale of some of its skin health and beauty brands, four people familiar with the matter said on Thursday, as the consumer health firm prunes an underperforming business segment to focus on core products. The company, which was spun out of Johnson & Johnson (JNJ.N), opens new tab in 2023, is zeroing in on smaller brands in the unit to sell such as Clean & Clear, Maui Moisture, Neostrata, its German baby care brand Bebe, and Japanese brand the sources said. It plans to hold onto the bigger names in the unit, such as Neutrogena and Aveeno, the sources said. There are about a dozen brands in the skin health and beauty unit, and sources cautioned that the divestiture package could change and no deal was guaranteed. Investment bankers at Goldman Sachs (GS.N), opens new tab are working with Kenvue on the divestment process, they added. Kenvue and Goldman declined to comment. The around half-dozen brands earmarked for sale would generate more than $500 million of revenue together, two of the sources said, a small portion of Kenvue's overall revenue, which was $15.5 billion in 2024. The skin health and beauty unit has been a drag on Kenvue's earnings, but the company has dedicated more money to marketing, especially on Neutrogena ad campaigns. The unit's organic sales declined 4.8% year-over-year in Kenvue's latest quarter that ended March 30. Kenvue, which also makes Tylenol and Band-Aids, has faced activist pressure over the last year from Starboard Value, Toms Capital Management and Third Point. It settled with Starboard in March, when it added the investment firm's founder to its board. Some of the activists have been pushing the company to consider selling itself or certain brands. In May, the company brought on new Chief Financial Officer Amit Banati from Kellanova(K.N), opens new tab , Kellogg's spun-out snacking unit.
